We are thrilled to be joining BVS at their Biotech Community Celebration at One Alexandria Square. This is the site of Lilly Gateway Labs, a biotech incubator that’s supporting the next wave of scientific breakthroughs. Come join us in meeting and collaborating with biopharma professionals from the wider San Diego ecosystem!
What is BVS?
Founded in 2003, Biotech Vendor Services (BVS) is a vendor neutral organization that hosts showcases, summits, and seminars with the goal of connecting scientists and suppliers. Their customized events provide a stimulating platform for attendees to exchange the latest discoveries and form meaningful connections.
Event Overview
Date: August 20th, 2026
Venue: Tribute Garden, One Alexandria Square, 10945 Alexandria Wy, San Diego, CA 92121
Event Schedule
For more information about BVS, please visit their website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
